Related Experiment Video

Updated: Jul 15, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

, B Simonsson

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |May 11, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    Related Experiment Videos

    Last Updated: Jul 15, 2026

    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
    09:57

    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

    Published on: March 5, 2018

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Physical mobility, physical activity, and obesity among elderly: findings from a large population-based Swedish survey.

    Public health·2017

    Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

    Leukemia·2016

    A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

    Leukemia & lymphoma·2016

    Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.

    Leukemia·2015

    The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

    Leukemia·2015

    Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

    Leukemia·2013

    Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

    Clinical pharmacology and therapeutics·2026

    INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

    Cancer research·2026

    Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

    Journal of comparative effectiveness research·2026

    Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

    Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

    Anti-cancer agents in medicinal chemistry·2026

    Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

    Anti-cancer agents in medicinal chemistry·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us